
    
      The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose
      Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates.

      The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the
      pharmacodynamics and therapeutic efficacy profile of BAT5906.
    
  